Fractioned Dose Regimen of Sunitinib for Patients with Gastrointestinal Stromal Tumor: A Pharmacokinetic and Treatment Efficacy Study()

AIM: Sunitinib has shown benefit in patients with imatinib (IM)–resistant gastrointestinal stromal tumor (GIST). However, its advantages are somewhat diminished because of associated toxicities. Herein, we clarify the efficacy and safety of fractioned dose regimen of sunitinib by a pharmacokinetic a...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Transl Oncol
Main Authors: Chen, Yen-Yang, Yeh, Chun-Nan, Cheng, Chi-Tung, Wu, Chao-En, Chiang, Kun-Chun, Chen, Tsung-Wen, Wang, Chih-Chi, Chen, Jen-Shi, Yeh, Ta-Sen
Formato: Artigo
Idioma:Inglês
Publicado em: Neoplasia Press 2014
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4225693/
https://ncbi.nlm.nih.gov/pubmed/25389456
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.tranon.2014.08.004
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados